Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta
NCT07096193Phase 2Recruiting
- Sponsor
- Gilead Sciences
- Start
- Jul 2025
- Primary completion
- Jan 2030
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of GS-4321 in hepatitis D (HDV), sponsored by Gilead Sciences. Started Jul 2025; status: recruiting.
02
Drugs
GS-4321
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on NCT07096193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07096193.